Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Technology
Share your love
AbbVie Introduces Refresh Tears PF and Refresh Relieva PF Xtra
AbbVie has introduced two new preservative-free (PF) lubricant eye drop products─Refresh Tears PF and Refresh Relieva PF Xtra. These new additions aim to enhance the options available for eye care with innovative features tailored for user convenience and eye health.…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Atsena & Nippon Shinyaku Partner on ATSN-101
Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…
Alcon Launches PRECISION7 One-Week Contact Lens
Alcon has announced the U.S. launch of PRECISION7, a groundbreaking contact lens designed for a convenient one-week replacement cycle. Incorporating the advanced 7-day ACTIV-FLO system, these lenses offer up to 16 hours of comfort and clear vision, even on the…
Santen, Arctic Vision to Launch ARVN001 in China
Clearside Biomedical has announced that Arctic Vision, its Asia-Pacific partner, has signed a commercial collaboration agreement with Santen Pharmaceutical Co. for ARVN001 (known in the United States as XIPERE) to treat uveitic macular edema (UME) and additional ophthalmic indications in…
FDA Approves LumiThera’s Valeda for Dry AMD Treatment
The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…
VSY Biotechnology Unveils Maestro® Sinusoidal IOL at ESCRS24
VSY Biotechnology to Complete Global Rollout of its Sinusoidal Vision Technology (SVT®) at ESCRS 2024 This year’s European Society of Cataract and Refractive Surgeons (ESCRS) 2024 kicked off with the highly anticipated third iNovation Day, which brought together the medical…
ChatGPT-4o Shows Promise in Addressing Retinal Diseases
A recent study highlights the potential of ChatGPT-4o in accurately answering questions related to retinal diseases, covering diagnostic criteria, treatment guidelines, and management strategies. The AI’s performance was evaluated by vitreoretinal specialists, focusing on its alignment with the American Academy of…